Bone-specific alkaline phosphatase; parathormone; bone turnover
Abstract :
[en] Background: Chronic Kidney Disease (CKD) is associated with mineral and bone disorders (MBD). International guidelines suggest that levels of serum parathormone (PTH) or bone-specific alkaline phosphatase (b-ALP) can be used to evaluate MBD in dialysis patients. The evidence remains moderate and based on transversal studies.
<br />Methods: We retrospectively investigated the variations of PTH (ΔPTH) and b-ALP (Δb-ALP) serum concentrations over a short (6-weeks) and a long (one-year) period in a monocentric hemodialysis population. The proportion of patients reaching the critical difference (CD) (50% for PTH and 25% for b-ALP) was calculated.
<br />Results: Seventy-seven patientswere included. A significant correlation between PTHand b-ALP levelswas found at baseline (r=0.51). By contrast, no correlation was observed between ΔPTH and Δb-ALP over a 6-week interval (r=0.07). The CD for PTH and b-ALP was reached by 19 and 11 patients, respectively, with 2 patients showing consistent variations of both biomarkers. One year later, measurements were repeated in 48 survivors.
<br />No correlation was found between ΔPTH and Δb-ALP (r=0.27). The CD for PTH or b-ALP was reached by 24 patients and 28 patients, respectively, with 6 patients (12.5%) showing opposite results for both biomarkers.
<br />Conclusion: This study shows the lack of correlation between ΔPTH and Δb-ALP over time in patients under chronic hemodialysis.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
DELANAYE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
DUBOIS, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
JOURET, François ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, S1-S130.
Urena P., Hruby M., Ferreira A., Ang K.S., de Vernejoul M.C. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996, 7:506-512.
Fletcher S., Jones R.G., Rayner H.C., et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997, 75:412-419.
Lehmann G., Ott U., Kaemmerer D., Schuetze J., Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3-5. Clin Nephrol 2008, 70:296-305.
Couttenye M.M., D'Haese P.C., Van Hoof V.O., et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996, 11:1065-1072.
Cavalier E., Delanaye P., Collette J., Krzesinski J.M., Chapelle J.P. Evaluation of different bone markers in hemodialyzed patients. Clin Chim Acta 2006, 371:107-111.
Reichel H., Esser A., Roth H.J., Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003, 18:759-768.
Jean G., Souberbielle J.C., Zaoui E., et al. Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease. Clin Biochem 2012, 45:436-439.
Cavalier E., Delanaye P., Vranken L., et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012, 27:1950-1956.
Sardiwal S., Gardham C., Coleman A.E., Stevens P.E., Delaney M.P., Lamb E.J. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 2012, 82:100-105.
Fraser C.G., Harris E.K. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989, 27:409-437.
Doumouchtsis K.K., Kostakis A.I., Doumouchtsis S.K., et al. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients. J Bone Miner Metab 2008, 26:66-72.
Nakashima A., Yorioka N., Doi S., Takasugi N., Shigemoto K., Kohno N. Osteoprotegerin and bone mineral density in hemodialysis patients. Osteoporos Int 2006, 17:841-846.
Tsuchida T., Ishimura E., Miki T., et al. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure. Osteoporos Int 2005, 16:172-179.
Urena P., Bernard-Poenaru O., Ostertag A., et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003, 18:2325-2331.
Bervoets A.R., Spasovski G.B., Behets G.J., et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003, 41:997-1007.
Mundy G.R., Guise T.A. Hormonal control of calcium homeostasis. Clin Chem 1999, 45:1347-1352.
Christenson R.H. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997, 30:573-593.
Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ. PTH-a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol in press, http://dx.doi.org/10.2215/CJN.09580911.
Sanchez C., Lopez-Barea F., Sanchez-Cabezudo J., et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004, 19:1587-1593.
Jean G., Chazot C., Charra B. 12months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 2007, 68:63-64.
